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Systemic toxicity is one of the major problems in chemotherapy. While 
the traditional chemotherapeutics generally affect all of the proliferating cells, 
new therapy modalities, in particular gene therapy, offer the possibility to 
selectively act in tumor cells. However, the high molecular weight of the 
active substances used in these treatment methods leads to unfavorable 
pharmacokinetic behavior that causes problems in the clinical application of 
these substances. Therefore, the success of these treatment methods 
depends on the development of new vector systems that enable transport of 
high molecular weight substances for example, oligonucleotides. Remarkable 
progress can be made here by chemical modifications [1]. 
 
Somatostatin-receptors (SSTRs) are found in numerous kinds of 
tumors (e.g., breast tumors, small-cell lung cancer). As the native peptide 
somatostatin is rapidly degraded in vivo, stabilized derivatives have been 
developed for clinical application. The most successful derivative is octreotide 
[2]. This peptide is able to induce endocytosis by binding to SSTRs and, 
because of the broad substrate specificity of these receptors, to mediate 
internalization of conjugated substances. That this can be used for the 
transport of tumor therapeutics has been shown in vitro for conjugates of the 
spindle poison taxol [3]. 
 
Since, up to now, it has not been possible to selectively transport 
antisense oligonucleotides into tumor cells, the question arose whether it 
would be possible to use SSTR-affine peptides as carriers for oligonucleotides. 
The oligonucleotide target sequence chosen was the anti-bcl-2- sequence [4, 
5]. It is quite difficult to generate the peptide– nucleic acid conjugates that 
are needed for this targeting concept by solid-phase synthesis. The standard 
methods for the synthesis of oligonucleotides and peptides are incompatible. 
Consequently, the conjugates are favorably generated by postsynthetic 
conjugation. We have recently reported on phosphorothioate oligonucleotides 
that are bound to a maleimido-modified SSTR-affine peptide through a thiol 
group at their 5’-end [6]. The conjugates showed high hybridization 
efficiency and a high affinity for SSTRs. In spite of the promising results that 
could be found in vitro, animal experiments revealed no significant 
enrichment in the tumors [7]. 
 
The pharmacokinetics of the phosphorothioates seemed to be 
dominated by strong unspecific interactions. Consequently, we chose the 
metabolically stable peptide nucleic acids (PNAs) for the experiments 
described herein [8]. The convergence of PNA and peptide synthesis enables 
the stepwise synthesis of PNA–peptide conjugates on the same polymeric 
support. Either 9-fluorenylmethoxycarbonyl (Fmoc) or tert-butyloxycarbonyl 
(Boc) chemistry are suitable for the synthesis of PNA oligomers. However, 
due to side reactions during deprotection of the Fmoc protecting group, the 
purity of the products produced by Boc chemistry is higher. To allow a 
convergent synthesis, the peptide part had to be built up by Boc chemistry as 
well. The PNA oligomers can be synthesized by using Boc chemistry in good 
yields, consequently this method is also suitable for the synthesis of PNA–
peptide conjugates [9]. 
 
Figure 1. Comparison of native somatostatin (A) with a conjugate consisting 
of a PNA and Tyr3-octreotate (B). The amino acids that are essential for 
receptor binding are marked in gray. 
 
Octreotate, which is nearly identical to octreotide except that it has a 
carboxy group at the C terminus and thus supports internalization (Figure 
1B), was chosen as the peptide part of the conjugate. Boc-D-Phe-Cys(Acm)-
Phe-D-Trp-Lys-Thr-Cys(Acm)-Thr-PAM resin was synthesized by application 
of a modified in situ neutralization protocol [10] with HATU as activator. The 
average coupling efficiency, determined by ninhydrin assay, was 99.1%. To 
enable the introduction of radioactive iodine (125I) an additional tyrosine 
residue was conjugated to the N-terminus, which led to the target molecule 1 
(base sequence=Tyr- AGC GTG CGC CAT CCC- peptide). 
 
 
During chain elongation in peptide and PNA synthesis, aggregation of 
the growing oligomer chain can be caused by either intra- or intermolecular 
interactions. This may lead to a collapse of the solid support and thus to low 
coupling efficiencies. The tendency for aggregation increases with increasing 
chain length. Consequently, the syntheses of long PNA–peptide conjugates is 
especially prone to the appearance of “difficult sequences”. Application of 
known synthesis protocols [11] did not lead to the anticipated success, thus, 
solvents, coupling times, the capping step, as well as the reaction conditions 
for the repeated coupling steps had to be optimized. The use of 
Ac2O/pyridine in DMF in the capping step proved to be essential. This was 
followed by a washing step with DMF/ piperidine to cleave possible acetyl 
esters. The coupling cycles were performed with five equivalents of the Boc-
protected PNA monomers using HATU as the activating agent. The exocyclic 
amino functions of the A, C, and G monomers were protected by 
benzyloxycarbonyl groups. The coupling cycle is shown schematically in 
Figure 2. 
 
 
 
  
Figure 2. Flow diagram of the synthesis cycle used for conjugating the PNA 
part (Boc chemistry). The abbreviations are defined in Scheme 1. 
 
 
 
 
Scheme 1. Flow diagram of the synthesis of the PNA–octreotate conjugate 
using Boc chemistry. a) Synthesis cycles with HATU/DIEA/Boc cleavage with 
5% p-cresol in TFA; b) Tl(TFA)3 ; c) synthesis cycles according to Figure 3; 
d) TFA /p-cresol/TFMSA. Protecting groups: Acm= acetamidomethyl, 2-Br-
Z=2-bromobenzyloxycarbonyl, 2-Cl-Z=2-chlorobenzyloxycarbonyl, Bzl= 
benzyl, For= formyl, Z= benzyloxycarbonyl, TFA= trifluoroacetic acid, 
TFMSA=trifluoro-methanesulfonic acid, DIPEA= N,N-diisopropylethylamine, 
HATU= O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluoro-
phosphate. 
 
 
 
Above a critical length of the oligomers, HPLC analysis of cleaved 
aliquots revealed strongly decreasing coupling efficiencies: after the 9th 
monomer, in particular when G monomers were conjugated, coupling 
efficiencies decreased to about 50%. By elongation of coupling times and by 
performing repeated couplings, the critical monomers could finally be coupled 
with coupling efficiencies of more than 95%. Using these optimized coupling 
conditions, we obtained the target conjugate in about 75% yield (according 
to HPLC analysis). However, it was not possible to cyclize this conjugate on 
the solid support, because the Tl3+ ions cause side reactions with the 
nucleobases. Owing to the size of the molecule, the course of the alternative 
air oxidation cannot be analyzed by HPLC. Therefore, the PNA oligomer was 
built up on the peptide which had been cyclized beforehand. Scheme 1 shows 
the synthesis of the octreoate–PNA conjugate from the peptide that was 
assembled by Boc chemistry and then cyclized by using Tl(TFA)3. After 
conjugation of the PNA monomers, a homogeneous product was obtained, 
which was deprotected with TFMSA in TFA using p-cresol as the scavenger. 
After precipitation with diethyl ether and subsequent purification by RP-HPLC, 
1 was isolated in about 40% yield. 
 
Binding experiments with the PNA conjugates using rat cortex 
membranes showed that the conjugates bind to SSTRs with a high affinity 
similar to that for octreotide, as confirmed by the IC50 values (octreotate–
PNA oligomer 1.52, octreotide 1.98 nM). Determination of the melting 
temperatures revealed that the PNA–conjugates hybridize with high affinity 
to the complementary phosphodiester–DNA oligonucleotides. The melting 
temperature of the conjugate was 82 ºC and thus much higher than that of a 
phosphodiester duplex of the same sequence (Tm=71.4 ºC). This shows that 
due to the high hybridizing affinity the PNA–conjugate should be suitable as 
an antisense drug. 
 
Organ distribution was evaluated in Lewis rats carrying the SSTR-
affine pancreatic tumor CA20948 (Figure 3). After deprotection and cleavage 
from the solid support, the PNA conjugate and a control PNA with the same 
sequence were labeled selectively with 125I at the tyrosine residue by using 
the Chloramine-T method [12]. In contrast to the phosphorothioate 
conjugate, for the 125I-labeled PNA–peptide conjugate, a selective enrichment 
in the tumor tissue was obtained. The physicochemical properties of the 
PNA–peptide conjugate are different to those of the Tyr3–octreotide. These 
properties influence factors like the interaction with serum proteins and 
result in different organ uptake, in particular in the kidney, the liver, and the 
lung. The modification of the PNA with the peptide part led to an about 
tenfold increase in tumor uptake. 
 
 
  
Figure 3. Organ distribution data for tumor-bearing Lewis rats, given in 
percent of the injected dose per gram of tissue (%IDg-1) ± standard deviation 
1 h after intravenous injection (average values from three or six animals, 
compounds were labeled with 125I). The conjugation of the peptide moiety 
causes a strongly increased accumulation of the PNA oligomer in the tumor 
tissue (statistical significance in students t-Test: p=0.021). 
 
In all of the organs except for the kidney, the enrichment of the 
octreotate conjugate resembles the accumulation of the free peptide. This 
indicates that the PNA–peptide conjugates in the serum are nonspecifically 
associated to a lower degree than the phosphorothioate conjugates, and are 
consequently better accessible for the binding to the receptors. The fact that 
79%of the tumor uptake can be inhibited by coinjection of an excess of 
nonlabeled octreotide provided further evidence for the receptor specificity of 
this uptake. 
 
Although there are some promising in vitro studies with PNA 
conjugates [13], none of the methods described could be successfully applied 
for the targeting of tumors in vivo. The use of SSTR-affine carrier molecules 
for the first time enables the targeted transport of oligonucleotides in tumor 
tissue. This demonstrates that targeting of high molecular weight drugs is 
possible by using receptor-specific peptides. 
 
 
Experimental Section 
 
Solid-phase syntheses were performed manually in a batch-procedure 
using Boc-protected amino acids (Bachem, Germany) as well as PNA 
monomers (Applied Biosystems, Germany) on a 4-(oxymethyl)- 
phenylacetamidomethyl-(PAM) resin. Analyses and purifications by RP-HPLC 
were performed on LiChrosorb RP-selectB columns (Merck KGaA, Germany) 
with gradient elution (water/acetonitrile (0.1%TFA)). Electrospray ionization 
mass spectrometry was carried out on a Finnigan MAT TSQ 7000 System 
(Thermo Finnigan, San Jose, USA). The radioisotope 125I was purchased from 
Amersham Pharmacia Biotech (Freiburg, Germany). 
 
Synthesis of the PNA–peptide conjugate: First, the following synthesis 
cycle was carried out to obtain H-D-Phe-cyclo[Cys-Phe-D-Trp(For)-Lys(2-Cl-
Z)-Thr(Bzl)-Cys]-Thr(Bzl)-O-PAM: The resin (100 mg; initial loading=0.72 
mmol g-1) was agitated with 5% p-cresol in TFA (two times for 2 min), and 
then washed with DMF, combined with a mixture of the carboxylic acid (4 
equiv), HATU (3.9 equiv) and diisopropylethylamine (DIPEA; 10 equiv) which 
had been pre-incubated for 2 min in DMSO, agitated for 2 min and again 
washed with DMF. The synthesis cycle for conjugating the PNA monomers to 
this resin was carried out as follows: a) agitation with TFA/p-cresol (95:5, 
v/v) two times for 2 min; b) incubation of the PNA monomers with HATU (4.9 
equiv) and DIPEA (10 equiv) for 2 min (final concentration 0.1M); c) washing 
with DMF/CH2Cl2 (1:1, v/v) and then with pyridine; d) agitation with the 
preactivated PNA monomer for 15 min; e) washing with DMF/ CH2Cl2 (1:1, 
v/v); f) agitation with Ac2O/pyridine/DMF (1:10:10, v/v/v) for 5 min; g) 
washing with DMF/ CH2Cl2 (1:1, v/v); h) agitation with DMF/ pyridine (95:5, 
v/v) for 2 min; i) washing with DMF/ CH2Cl2 (1:1, v/v). After the coupling of 
Boc-Tyr(2-Br-Z) the resin was washed and dried. The loaded resin (30 mg) 
was mixed with 5% p-cresol (500 µL) in TFA. After the addition of TFMSA (50 
µL), the resin was agitated for 2 h, filtered off, and the raw product was 
precipitated with diethyl ether. The raw product was resolubilized in 
acetonitrile/water (1:1) and incubated for 24 h at room temperature. The 
sample was purified by HPLC. After lyophilization, H-Tyr-AGC GTG CGC CAT 
CCC-D-Phe-cyclo[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-OH was obtained as a 
white powder (overall yield: 16.8 mg; ca. 40%). The integrity and purity of 
the product was confirmed with ESI-MS (m/z for C218H270N96O58S2 calcd: 5203 
gmol-1, found: 5205 gmol-1 ([M+H]+) and analytical HPLC (purity >95%).  
 
The control PNA (H-Tyr-AGC GTG CGC CAT CCC-Lys-NH2) was 
synthesized analogous to the PNA–peptide conjugate. 
 
Organ distribution studies: A cell suspension of the CA20948 tumor in 
a nutrient mixture was subcutaneously administered into the nape of the 
neck of male Lewis rats. After about 10 days, the tumors were grown to a 
volume of about 5 mL. The 125I-labeled compound was injected into the tail 
vein of the animals (groups of three animals). After 1 h, the animals were 
sacrificed and the activity concentration of the dissected organs was 
determined in a γ-counter. 
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